Back

Acoramidis treatment attenuates the rise in N-terminal pro-B-type natriuretic peptide from baseline to month 30 compared with placebo across participant subgroups in ATTRibute-CM

10 May 2026 (15:30 - 16:15)
Organised by: Logo
Congress Presentation Part of: Cardiac amyloidosis: therapeutic strategies and clinical outcomes Clinical HFA Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Professor Marianna Fontana

University College London, London (United Kingdom of Great Britain & Northern Ireland)

4 More presentations in this session

Presentation thumbnail
Influence of Vutrisiran on Systolic Blood Pressure in ATTR-CM: HELIOS-B
Doctor A. Sheikh (London, GB)
Abstract Slides
Presentation thumbnail
Anchored matching-adjusted indirect comparison of acoramidis (ATTRibute-CM) vs tafamidis (ATTR-ACT) for risk of cardiovascular-related hospitalization, all-cause mortality and safety in ATTR-CM
Doctor E. Joyce (Dublin, IE)
Abstract Slides
Presentation thumbnail
Longitudinal changes in PYP heart-to-contralateral lung ratio and echocardiographic diastolic parameters in ATTR cardiac amyloidosis treated with tafamidis
Doctor R. Gabarin (London, CA)
Abstract Slides
Presentation thumbnail
Rationale and design of ACO-SWITCH - a phase 4 study evaluating serum transthyretin levels in patients with ATTR-CM who switched from tafamidis to acoramidis
Associate Professor R. Pfister (Cologne, DE)
Abstract Slides

Access the full session

Session thumbnail
Cardiac amyloidosis: therapeutic strategies and clinical outcomes

The Event

Event poster

Heart Failure 2026

10 May 2026 15:30 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources